Xentria

10 articles about Xentria

• Xentria’s XTMAB-16 Receives Orphan Drug Designation From European Medicines Agency as First Patient is Enrolled in Study

  11/15/2023

  Xentria announces major milestone of first patient enrolled in The XTMAB16 Study evaluating TNFα inhibitor for the treatment of sarcoidosis.

• Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America

  6/27/2023

  Xentria Inc. and Meitheal Pharmaceuticals, Inc. announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.

• Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

  3/21/2023

  Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal.

• Xentria Announces $25 Million Equity Financing Round to Advance Pipeline and Execute on Growth Strategy

  10/18/2022

  Xentria Inc. announced a $25 million growth equity funding round approved by its Board of Directors and the opening of a new corporate headquarters.

• Xentria Appoints Lead Scientific Advisor and Chief Operating Officer

  8/4/2022

  Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, made key leadership appointments, naming Dr. Robert Baughman as Lead Scientific Advisor and Kirsten Anderson as Chief Operating Officer.

• Xentria Announces Initial Findings Showing Novel Biologic XTMAB-16’s Potential to Reduce Sarcoidosis Granuloma

  6/23/2022

  Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.

• Xentria to Present Initial Findings from Preclinical Study of XTMAB-16 at ATS 2022 International Conference

  3/8/2022

  Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, announced that a new abstract showcasing XTMAB-16’s potential effect on sarcoidosis granuloma formation will be presented at the upcoming American Thoracic Society 2022 International Conference being held in San Francisco, CA from May 13-18, 2022.

• Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis

  6/22/2021

  Xentria Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that the Company satisfactorily addressed all requirements and can proceed with initiation of the planned Phase 1 clinical trial of XTMAB-16.

• Xentria Announces Submission of an Investigational New Drug (IND) Application for XTMAB-16 in the Treatment of Sarcoidosis

  3/3/2021

  Xentria Inc., a biopharmaceutical company focused on developing novel biologics and biosimilars to address unmet clinical needs, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on February 26, 2021.

• Xentria Announces FDA Orphan Drug Designation for XTMAB-16 in Sarcoidosis

  12/15/2020

  Xentria, Inc., a biopharmaceutical company focused on developing novel biologics and biosimilars to address unmet clinical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its intravenous TNF-α inhibitor, XTMAB-16, for the treatment of sarcoidosis.